| | Audit Committee | Compensation Committee | Nominating, Governance & Review Committee |
| Outside Directors |
Spencer R. Berthelsen, M.D. Spencer R. Berthelsen, M.D.
Chairman of the Board and Managing Director, Kelsey-Seybold Clinic
Dr. Berthelsen has served as a Director of Isis since May 2002. Since 1980, he has practiced Internal Medicine with the Kelsey Seybold Clinic, a 350 physician medical group based in the Texas Medical Center in Houston. Dr. Berthelsen has served in various senior leadership positions at Kelsey Seybold, including Chairman of the Department of Internal Medicine, Medical Director and Managing Director. He has been Chairman of their Board of Directors since October 2001. He is a Clinical Professo... |
|
|
|
| Richard D. DiMarchi, Ph.D. Richard D. DiMarchi, Ph.D.
Professor and Linda & Jack Gill Chair, Biomolecular Science, Indiana University
Richard D. DiMarchi, Ph.D. has served as a Director of Isis since December 2004. Dr. DiMarchi has been a Professor and the Jack and Linda Gill Distinguished Chair in Biomolecular Science at Indiana University, Bloomington, Indiana since August 2003. He previously served as Chairman of the Chemistry Department, and is a co-founder of Marcadia Biotech and Ambrx, Inc., privately held biotechnology companies. Prior to joining Indiana University, Dr. DiMarchi worked for 22 years at Eli Lilly and C... |
| |
| | Joseph Klein, III Joseph Klein, III
Managing Director, Gauss Capital Advisors, LLC
Mr. Klein has served as a Director of Isis since December 2005. Mr. Klein is currently Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. From September 2003 to December 2008, Mr. Klein also served as a Venture Partner of Red Abbey Venture Partners, L.P., a life science private equity fund. From September 2001 to September 2002, Mr. Klein was a Venture Partner of MPM Capital, a he... |
|
| | | Frederick T. Muto, Esq. Frederick T. Muto, Esq.
Partner, Cooley Godward Kronish LLP
Frederick T. Muto has served as a Director of Isis since March 2001. Mr. Muto joined the law firm of Cooley Godward Kronish LLP, outside counsel to Isis, in 1980 and became a partner in 1986. He is a founding partner of Cooley Godward Kronish LLP’s San Diego office and serves as the partner in charge of that office. Mr. Muto also serves on that firm’s executive, management and compensation committees.... |
| | | | John C. Reed, M.D., Ph.D. John C. Reed, M.D., Ph.D.
Chief Executive Officer, Professor and Donald Bren Chief Executive Chair, Sanford-Burnham Medical Research Institute
Dr. Reed has served as a Director of Isis since February 2002. Dr. Reed is the Chief Executive Officer of Sanford-Burnham Medical Research Institute, an independent, nonprofit, public benefit organization dedicated to basic and translational biomedical research, since January 2002. Dr. Reed has been with Sanford-Burnham Medical Research Institute for the past sixteen years, serving in position of increasing authority, including the Deputy Director of the Cancer Center beginning in 1994, as Scie... |
| |
|
| Joseph H. Wender Joseph H. Wender
Senior Consultant, Goldman Sachs & Co.
Mr. Wender has served as a Director of Isis since January 1994. Mr. Wender began with Goldman, Sachs & Co. in 1971 and became a General Partner of that firm in 1982, where he headed the Financial Institutions Group for over a decade. Mr. Wender worked at GSC Group from 2005 through 2007 where he was a Senior Managing Director, member of the Management Committee, and Chairman of the Finance Committee. Since January 2008, he has been a Senior Consultant to Goldman Sachs & Co. He is also an Ind... |
|
| | |
| Inside Directors |
Stanley T. Crooke, M.D., Ph.D. Stanley T. Crooke, M.D., Ph.D.
Chairman of the Board and Chief Executive Officer, Isis Pharmaceuticals, Inc.
Untitled Document
Dr. Crooke is Founder, Chairman and Chief Executive Officer of Isis Pharmaceuticals. Since Dr. Crooke and his colleagues founded Isis in 1989, the Company completed its initial public offe... |
| | | | B. Lynne Parshall, Esq. B. Lynne Parshall, Esq.
Director, Chief Operating Officer & Chief Financial Officer, Isis Pharmaceuticals, Inc.
Ms. Parshall is Director, Chief Operating Officer and Chief Financial Officer of Isis Pharmaceuticals. She is responsible for overseeing the operations of finance, legal, patents, manufacturing, and business development and is also very involved in the Company’s corporate communications activities. Ms. Parshall joined Isis in November 1991.
Previously, Ms. Parshall was a Partner with the firm of Cooley Godward LLP, now Cooley Godward Kronish LLP, where she represented sever... |
| | | |
|
Financial Expert